Last reviewed · How we verify
NCT04456621
Proton Beam Therapy for Unresectable Liver Metastasis
NA trial testing PBT in Local Control Rate in 66 participants. Completed in 31 July 2021.
30 June 2021
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 1 January 2019 |
| Primary completion | 30 June 2021 |
| Estimated completion | 31 July 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- PBT
Conditions studied
- Local Control Rate — all drugs for Local Control Rate →
- Side Effect — all drugs for Side Effect →
Sponsor
Samsung Medical Center
Who can join
20 and older, any sex, with Local Control Rate or Side Effect. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators performed the present study to evaluate the role of proton beam therapy for liver metastasis which is unresectable and unsuitable for radiofrequency ablation (RFA) in terms of local control and safety.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy.
Yoo GS, Rim CH, Cho WK, Jeong JU, et al · · 2023 · cited 3× · PMID 36960629 · DOI 10.4143/crt.2022.1599 -
Clinical Evidence on Particle Radiation, DNA Damage Response Inhibitors, and Immunotherapy for Mismatch Repair-Proficient Rectal Cancer
Salazar-Vilches C, Ebner D, Kloeber J, Dragojevic S, et al · · 2026
Verify or expand the search:
- PubMed search for NCT04456621
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04456621 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 22 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04456621.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing